Alexander Ondari, MD
Family Medicine · Fort Wayne, INNPI 1891057535
Payments from drug & device makers
Across 266 payments — averaging $40.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$965
- Lilly USA, LLC$758
- Axsome Therapeutics, Inc.$680
- Amgen$559
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$2002%
- Food & beverage$10,51498%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $2,066 |
| Novo Nordisk | 33 | $1,365 |
| GSK | 12 | $965 |
| Lilly USA, LLC | 19 | $758 |
| Axsome Therapeutics, Inc. | 12 | $680 |
| Amgen | 17 | $559 |
| AstraZeneca | 15 | $551 |
| Phathom Pharmaceuticals, Inc. | 5 | $504 |
| Bayer | 19 | $394 |
| Sanofi-aventis U.S. LLC | 6 | $391 |
| Otsuka America Pharmaceutical, Inc. | 8 | $385 |
| Teva Pharmaceuticals USA, Inc. | 7 | $233 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $214 |
| Eko Health, Inc. | 1 | $200 |
| Vanda Pharmaceuticals Inc. | 6 | $184 |
| Pfizer | 8 | $156 |
| Johnson & Johnson | 3 | $154 |
| Urgo Medical North America, LLC | 1 | $141 |
| Mylan Specialty L.p. | 1 | $115 |
| Eisai Inc. | 1 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $96 |
| Astellas Pharma US Inc | 4 | $88 |
| Exact Sciences | 4 | $67 |
| Dexcom, Inc. | 3 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Merck | 2 | $38 |
| Lundbeck LLC | 2 | $37 |
| Abbott | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,773 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $184,216 |
| MounjaroTirzepatide | 99 | $130,659 |
| TrulicityDulaglutide | 31 | $48,705 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $47,499 |
| RybelsusSemaglutide | 28 | $45,945 |
| EliquisApixaban | 14 | $21,161 |
| FarxigaDapagliflozin Propanediol | 12 | $20,785 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $13,005 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $6,400 |
| JardianceEmpagliflozin | 11 | $6,030 |
| Novolog FlexpenInsulin Aspart | 17 | $5,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 134 | $4,029 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,834 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,631 |
| Atorvastatin Calcium | 450 | $3,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,365 | $230,161151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $758 | $179,364130 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $965 | $64,33894 claims |
| PfizerEliquis | $156 | $21,16114 claims |
| AstraZenecaFarxiga | $551 | $20,78512 claims |
| Boehringer IngelheimJardiance | $33 | $6,03011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.